Purdue Pharma LP
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1892-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://www.purduepharma.com
Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Chronic Low Back Pain
- Conditions
- Low Back Pain
- Interventions
- Drug: Placebo
- First Posted Date
- 2007-06-25
- Last Posted Date
- 2012-09-10
- Lead Sponsor
- Purdue Pharma LP
- Target Recruit Count
- 539
- Registration Number
- NCT00490919
- Locations
- 🇺🇸
Dolby Research, LLC, Baton Rouge, Louisiana, United States
🇺🇸Arizona Research Center Inc., Phoenix, Arizona, United States
🇺🇸Pharmax Research Clinic, Miami, Florida, United States
An Open-label Study of Hydromorphone Oral Solution in Subjects Aged 28 Days to 16 Years for Postoperative Pain
- First Posted Date
- 2007-04-25
- Last Posted Date
- 2015-11-18
- Lead Sponsor
- Purdue Pharma LP
- Target Recruit Count
- 116
- Registration Number
- NCT00465647
- Locations
- 🇺🇸
Children's Hospital Medical Center of Akron, Akron, Ohio, United States
🇺🇸Children's Hospital of Orange County - Pediatric Subspecialty, Orange, California, United States
🇺🇸Stanford University Medical Center, Stanford, California, United States
Safety of Buprenorphine Transdermal System (BTDS) in Subjects With Acute Postoperative Pain After Total Knee Replacement
- Conditions
- Postoperative Pain
- Interventions
- Drug: Placebo BTDS
- First Posted Date
- 2006-11-23
- Last Posted Date
- 2012-09-03
- Lead Sponsor
- Purdue Pharma LP
- Target Recruit Count
- 10
- Registration Number
- NCT00403234
- Locations
- 🇺🇸
Arizona Research Center, Phoenix, Arizona, United States
🇺🇸Greater Chesapeake Orthopaedic Associates, Baltimore, Maryland, United States
🇺🇸Southeastern Clinical Research Consultants, Orlando, Florida, United States
Efficacy and Safety of Hydromorphone Hydrochloride Extended-Release Compared to Placebo in Subjects With Persistent Pain
- Conditions
- Chronic Non-Malignant Pain
- First Posted Date
- 2006-08-18
- Last Posted Date
- 2006-08-18
- Lead Sponsor
- Purdue Pharma LP
- Target Recruit Count
- 380
- Registration Number
- NCT00365898
- Locations
- 🇺🇸
Clinical Research of West Florida, Inc. 2147 NE Coachman Road, Clearwater, Florida, United States
🇺🇸PharmQuest 301 E Wendover Avenue Suite 411, Greensboro, North Carolina, United States
🇺🇸Arizona Research Center 2525 W. Greenway Rd. Suite 114, Phoenix, Arizona, United States
Buprenorphine Transdermal Patches (BTDS) in Subjects With Osteoarthritis Pain. Includes a 52-week Extension Phase.
- First Posted Date
- 2006-05-03
- Last Posted Date
- 2012-09-03
- Lead Sponsor
- Purdue Pharma LP
- Target Recruit Count
- 188
- Registration Number
- NCT00320801
- Locations
- 🇺🇸
Comprehensive Clinical Research, Berlin, New Jersey, United States
🇺🇸Southern Oregon Health & Wellness, Medford, Oregon, United States
🇺🇸Sidney Hillman Medical Center, Philadelphia, Pennsylvania, United States
The Safety and Efficacy of the Buprenorphine Transdermal Delivery System in Subjects With Chronic Low Back Pain.
- Conditions
- Back Pain
- First Posted Date
- 2006-04-19
- Last Posted Date
- 2013-05-14
- Lead Sponsor
- Purdue Pharma LP
- Target Recruit Count
- 225
- Registration Number
- NCT00315874
- Locations
- 🇺🇸
Metroplex Clinical Research Center, Dallas, Texas, United States
🇺🇸Gainesville Clinical Research Center, Gainesville, Florida, United States
🇺🇸Pain Control Ctr Bowman Gray School of Med, Winston-Salem, North Carolina, United States
The Safety and Efficacy of the Buprenorphine Transdermal Delivery System in Subjects With Osteoarthritis Pain.
- Conditions
- Osteoarthritis
- First Posted Date
- 2006-04-19
- Last Posted Date
- 2006-05-03
- Lead Sponsor
- Purdue Pharma LP
- Target Recruit Count
- 225
- Registration Number
- NCT00315848
- Locations
- 🇺🇸
MediSphere Medical Research Center, L.L.C., Evansville, Indiana, United States
🇺🇸Metroplex Clinical Research Center, Dallas, Texas, United States
🇺🇸Rheumatology Associates of North Alabama, Huntsville, Alabama, United States
The Safety and Efficacy of the Buprenorphine Transdermal Delivery System in Subjects With Chronic Back Pain.
- Conditions
- Chronic Low Back Pain
- First Posted Date
- 2006-04-19
- Last Posted Date
- 2006-05-03
- Lead Sponsor
- Purdue Pharma LP
- Target Recruit Count
- 250
- Registration Number
- NCT00315887
- Locations
- 🇺🇸
Mid-America Rheumatology Consultants, Overland Park, Kansas, United States
🇺🇸Evergreen Clinical Research, Edmonds, Washington, United States
🇺🇸Gainesville Clinical Research Center, Gainesville, Florida, United States
Safety of the Buprenorphine Transdermal Delivery System in Subjects With Mod-to-Sev Pain Following Orthopedic Surgery.
- Conditions
- Postoperative Pain
- First Posted Date
- 2006-04-19
- Last Posted Date
- 2006-04-19
- Lead Sponsor
- Purdue Pharma LP
- Target Recruit Count
- 100
- Registration Number
- NCT00315835
- Locations
- 🇺🇸
Park Place Therapeutic Center, Plantation, Florida, United States
Buprenorphine Transdermal Patch in Subjects With Osteoarthritis Pain Requiring Opioids. Includes a 52-Week Safety Extension.
- Conditions
- Osteoarthritis
- Interventions
- Drug: Placebo transdermal patch
- First Posted Date
- 2006-04-18
- Last Posted Date
- 2012-09-03
- Lead Sponsor
- Purdue Pharma LP
- Target Recruit Count
- 107
- Registration Number
- NCT00315458
- Locations
- 🇺🇸
Avancia Research, Pembroke Pines, Florida, United States
🇺🇸Palm Beach Research Center, West Palm Beach, Florida, United States
🇺🇸University Orthopedics Center, State College, Pennsylvania, United States